Women with metastatic breast cancer in the Netherlands reportedly cannot receive reimbursement for the medicine Enhertu, while reimbursement is available in other European countries. The price has not been reduced enough to reach an agreement in the Netherlands, raising questions about whether sufficient attention is being paid to patients.